Related Experiment Video

Updated: Jul 6, 2026

Quantification of Monocyte Transmigration and Foam Cell Formation from Individuals with Chronic Inflammatory Conditions
09:41

Quantification of Monocyte Transmigration and Foam Cell Formation from Individuals with Chronic Inflammatory Conditions

Published on: October 17, 2017

[Effect of simvastatin on monocyte CX3CR1 expression in patients with acute coronary syndrome]

Dan-dan Peng1, Zhi-liang Li

  • 1Department of Cardiology, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China. pdd009@126.com

Nan Fang Yi Ke Da Xue Xue Bao = Journal of Southern Medical University
|March 25, 2008
PubMed

Insights

Simvastatin significantly reduces CX3CR1 expression in monocytes from acute coronary syndrome patients. This finding suggests non-lipid mechanisms for statins in atherosclerosis treatment and plaque stabilization.

Area of Science:

  • Cardiovascular Medicine
  • Immunology
  • Pharmacology

Background:

  • Atherosclerosis involves inflammation driven by monocyte recruitment.
  • CX3CR1 (fractalkine receptor) plays a role in monocyte adhesion and inflammation.
  • Statins are known for lipid-lowering effects, but non-lipid mechanisms are under investigation.

Purpose of the Study:

  • To investigate the effect of simvastatin on CX3CR1 expression in monocytes from patients with acute coronary syndrome (ACS).
  • To explore potential non-lipid-dependent anti-atherosclerotic mechanisms of simvastatin.

Main Methods:

  • Quantitative real-time RT-PCR was used to measure CX3CR1 gene expression.
  • Monocytes from 63 ACS patients were treated with simvastatin (10(-7) to 10(-5) mol/L) for 4, 8, and 12 hours.
  • Simvastatin concentrations and treatment durations were varied to assess dose- and time-dependency.

Main Results:

  • Simvastatin treatment significantly decreased CX3CR1 expression in monocytes compared to control cells (P<0.05).
  • The reduction in CX3CR1 expression was observed across different simvastatin concentrations and treatment durations (P<0.01).
  • Results indicate a concentration- and time-dependent effect of simvastatin on CX3CR1.

Conclusions:

  • Simvastatin effectively reduces CX3CR1 expression in monocytes from ACS patients.
  • This reduction may contribute to decreased inflammation and improved vascular plaque stability.
  • The findings highlight potential non-lipid-mediated benefits of simvastatin in managing atherosclerosis.
Abstract

More Related Videos

On-Chip Endothelial Inflammatory Phenotyping12:43

On-Chip Endothelial Inflammatory Phenotyping

Published on: July 21, 2012

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...